The Metabolic Syndrome and Microbiota-Gut-Brain Axis—Is There a Link?

Metabolic syndrome (MetS), with obesity as its primary pathogenic driver, is a major public health concern and a leading risk factor for type 2 diabetes (T2D) and cardiovascular disease. Increasing evidence highlights the critical role of the microbiota-gut-brain axis (MGBA) in the pathogenesis of these disorders through its regulation of energy homeostasis, metabolic function, and immune responses. This review summarizes current evidence on the mechanisms by which disturbances in MGBA signaling contribute to the development and progression of MetS. Gut microbiome dysbiosis may increase intestinal permeability, facilitating the translocation of bacterial lipopolysaccharide into the systemic circulation. This process may contribute to metabolic endotoxemia and chronic low-grade inflammation, potentially promoting insulin resistance, adipose tissue dysfunction, and metabolic impairment. In addition, alterations in microbiome composition and function influence the secretion of gut-derived hormones, vagal signaling, hypothalamic–pituitary–adrenal axis activity and bile acid metabolism, ultimately disrupting appetite regulation, glucose homeostasis, lipid metabolism and blood pressure control. Preclinical studies and limited clinical evidence suggest that gut microbiota-targeted interventions, including prebiotics and probiotics, may improve selected metabolic parameters. However, evidence demonstrating sustained clinical benefits or reductions in cardiometabolic events in patients with MetS remains insufficient. Although the MGBA represents a potential therapeutic target, further well-designed randomized controlled trials with predefined metabolic outcomes, direct assessment of microbial function, and adequate follow-up are needed to establish the clinical efficacy and long-term safety of microbiota-targeted interventions, including fecal microbiota transplantation (FMT).

Authors

Institutions

Publication Details

Journal
Nutrients
Published
2026-11-13
DOI
https://doi.org/10.3390/nu18223780
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Metabolic Syndrome and Microbiota-Gut-Brain Axis—Is There a Link?

Marta Pelczyńska, Paweł Bogdański, Małgorzata Moszak, Starosta Szymon et al.
4 links
Nutrients
Gut microbiota and health
article

The Metabolic Syndrome and Microbiota-Gut-Brain Axis—Is There a Link?

Marta Pelczyńska, Paweł Bogdański, Małgorzata Moszak, Starosta Szymon, Stanisław Pogonowski, Michał Rodziak, Emilia Adamczak
article en

Abstract

Metabolic syndrome (MetS), with obesity as its primary pathogenic driver, is a major public health concern and a leading risk factor for type 2 diabetes (T2D) and cardiovascular disease. Increasing evidence highlights the critical role of the microbiota-gut-brain axis (MGBA) in the pathogenesis of these disorders through its regulation of energy homeostasis, metabolic function, and immune responses. This review summarizes current evidence on the mechanisms by which disturbances in MGBA signaling contribute to the development and progression of MetS. Gut microbiome dysbiosis may increase intestinal permeability, facilitating the translocation of bacterial lipopolysaccharide into the systemic circulation. This process may contribute to metabolic endotoxemia and chronic low-grade inflammation, potentially promoting insulin resistance, adipose tissue dysfunction, and metabolic impairment. In addition, alterations in microbiome composition and function influence the secretion of gut-derived hormones, vagal signaling, hypothalamic–pituitary–adrenal axis activity and bile acid metabolism, ultimately disrupting appetite regulation, glucose homeostasis, lipid metabolism and blood pressure control. Preclinical studies and limited clinical evidence suggest that gut microbiota-targeted interventions, including prebiotics and probiotics, may improve selected metabolic parameters. However, evidence demonstrating sustained clinical benefits or reductions in cardiometabolic events in patients with MetS remains insufficient. Although the MGBA represents a potential therapeutic target, further well-designed randomized controlled trials with predefined metabolic outcomes, direct assessment of microbial function, and adequate follow-up are needed to establish the clinical efficacy and long-term safety of microbiota-targeted interventions, including fecal microbiota transplantation (FMT).

NutrientsVol. 18(22)
Poznan University of Medical Sciences (PL)
Good health and well-being
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon